# TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

> **NCT04561986** · PHASE3 · RECRUITING · sponsor: **Vastra Gotaland Region** · enrollment: 50 (estimated)

## Conditions studied

- Antibody-mediated Rejection

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04561986
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-01
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-04-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04561986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04561986, "TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04561986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*